INVESTORS & MEDIA
News Release
Regeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2020
Conference Call Information
To access this call, dial (800) 708-4540 (U.S.) or (847) 619-6397 (International). A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at http://investor.regeneron.com/events.cfm. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days.
About Regeneron
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, including VelocImmune® which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information: |
|
Investor Relations |
Corporate Communications |
Justin Holko |
Hala Mirza |
914.847.7786 |
914.847.3422 |
View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2019-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-6-2020-300984444.html
SOURCE